Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Biotechnology

Healthcare
$4.48 -1.44%

-$0.12 today

Market cap
$283.23M
Beta
1.96
P/E (TTM)
-3.1
EPS (TTM)
-$2.59
52W Low $2.52High $13.67

Volume 1.05M

Average 0.94M

KYTX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Kyverna Therapeutics, Inc.NASDAQ: KYTX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $11.29M rose 13.2% year over year, behind the +18.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 21.9% from the prior quarter. Over 3 fiscal years it compounded at +65.2% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $13.07M (-63.8%) for the fiscal year ending Dec 2026, a slowdown from the +19.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.29M+21.9% QoQ
Last fiscal yearDec 2025
$36.11M+19.8% YoY
LTMMar 2026
$37.43M+18.7% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.2%-100.0%-113.2 pp
1 year+19.8%-63.8%-83.6 pp
3-year CAGR+65.2%+15.5%-49.7 pp
5-year CAGR+72.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
36.11M USD
Year-over-year change
+19.8%
4-year CAGR
+55.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How KYTX compares with its peers on the latest reported figures

  • KYTX's LTM Mar 2026 selling, general & admin of $37.43M is the 4th highest of the 11 companies compared; the peer median is $29.34M.
  • Its year-over-year change of +18.7% is the 2nd highest of 10, against a peer median of -13.0%.
  • Over three fiscal years its annual growth of +65.2% compares with a peer median of +1.0%.
KYTX Competitors Peer median
Selling, General & Admin for KYTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$55.88M -11.2%-10.5%—
EDITEditas Medicine, Inc.LTM Mar 2026$46.76M -29.2%-11.0%120.9%
LYELLyell Immunopharma, Inc.LTM Mar 2026$40.64M -22.7%-27.3%131109.7%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$37.43M +18.7%+65.2%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$35.46M -13.0%+55.9%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$30.28M -34.0%-12.3%—
CABACabaletta Bio, Inc.LTM Mar 2026$28.39M -5.3%+25.8%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$26.76M +58.7%+29.7%—
SLNSilence Therapeutics plcLTM Mar 2026$23.59M —+2.2%2560.2%
MREOMereo BioPharma Group plcLTM Mar 2026$19.76M -28.1%-0.2%3951.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$17.4M +18.2%+41.6%—
Peer median (excluding KYTX) $29.34M-13.0%+1.0%3255.6%

Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.66M7.03M000
Cost of Revenue001.71M2.13M0
Gross Profit5.66M7.03M(1.71M)(2.13M)0
Gross Margin100.0%100.0%———
Research & Development25.85M28.4M48.22M112.47M133.72M
Selling, General & Admin6.15M8.01M12.48M30.13M36.11M
Operating Expenses32M36.41M60.7M140.47M169.83M
Depreciation & Amortization586K1.05M1.71M2.13M1.8M
EBITDA(25.76M)(27.78M)(58.47M)(125.2M)(159.02M)
EBITDA Margin-455.5%-395.4%———
Operating Income(26.35M)(29.38M)(62.41M)(142.6M)(169.83M)
Operating Margin-465.8%-418.3%———
Interest Income1K565K2.28M15.36M9.09M
Interest Expense3K65K187K142K489K
Other Income / Expenses(4K)491K2.04M15.13M8.52M
Income Before Tax(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Pre-Tax Margin-465.9%-411.3%———
Income Tax Expense00000
Net Income(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Net Margin-465.9%-411.3%———
EPS (Basic)(1.02)(1.12)(0.00)(3.33)(3.64)
EPS (Diluted)(1.02)(1.12)(0.00)(3.33)(3.64)
Weighted Avg Shares25.8M25.8M673.62M38.33M44.26M
Weighted Avg Shares (Diluted)25.8M25.8M673.62M38.33M44.26M

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Intrinsic Alpha fair value

Locked

Current Price

$4.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.